Open AccessRefractory sickle cell leg ulcer: is heparan sulphate a new hope?
Author(s) -
Hayek Shady,
Dibo Saad,
Baroud Joe,
Ibrahim Amir,
Barritault Denis
Publication year - 2016
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12217
Subject(s) - medicine , refractory (planetary science) , cell , disease , gastroenterology , leg ulcer , surgery , biochemistry , chemistry , physics , astrobiology
Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy. This study reports the successful use of synthetic heparan sulphate (Cacipliq20 ® , OTR3, Paris, France) in the treatment of a sickle cell ulcer that had failed to respond to several other means of treatment. Therapeutic success was assessed by complete wound coverage and vast improvement in pain score. This is the first study to report use of heparan sulphate in sickle cell ulcers.